Lilly CEO Says Europe Needs Incentives To Reward Innovators, Investors
This article was originally published in The Pink Sheet Daily
Eli Lilly CEO John Lechleiter says Europe needs better pricing and access policies if the region wants to stop and reverse its decline in drug innovation.
You may also be interested in...
In its most ambitious overhaul since the reorganization into iMeds in 2010, AstraZeneca’s latest R&D restructuring takes on three basic challenges: accessing innovation, improving internal productivity and reducing complexity and cost. It is the opening salvo in the new CEO’s vision for the troubled pharma.
The efficiency program outlined by the German pharma in February will mean elimination of 500 Merck Serono staff in Switzerland, with another 750 employees being redeployed to Germany, China or the U.S.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.